1. Home
  2. Programs
  3. CME/CE
advertisement

Addressing the Unmet Needs of Refractory Chronic Cough

60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
  • Overview

    Refractory chronic cough (RCC) presents persistent diagnostic and treatment challenges that can significantly impact patients' quality of life. Join experts from the American Thoracic Society (ATS) and explore evidence-based diagnostic strategies, the neurobiology of cough hypersensitivity, and emerging targeted therapies. Discover how evolving clinical research may shape future treatment approaches and help improve outcomes for patients living with RCC.

  • Disclosure of Relevant Financial Relationships

    It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers, and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org).

    Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

    Amanda Noe, TFF Staff, has no relevant financial relationships to disclose.

    Emily Casabar, MSN, NP-C, AE-C, Planning Committee Member, has served as a consultant for Sanofi and Regeneron. To mitigate potential conflicts of interest, all final planning decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted planning committee member. Content was also reviewed by a non-conflicted planning committee member to ensure it was free from commercial bias, fair-balanced, and based on scientific evidence and/or clinical reasoning.

    Erika Fox, TFF Staff, has no relevant financial relationships to disclose.

    Lauren Eggert, MD, Planning Committee Member and Faculty, has served as a consultant for AstraZeneca, GlaxoSmithKline, Nestwell Health, and Regeneron, and as a speaker for GlaxoSmithKline and Sanofi.

    Melissa Glasner, MSc, Planning Committee Member and TFF Content Reviewer, has no relevant financial relationships to disclose.

    Nicholas Klock, PA-C, Planning Committee Member, has no relevant financial relationships to disclose.

    Peter Dicpinigaitis, MD, Planning Committee Member and Faculty, has served as a consultant for GlaxoSmithKline, Hyfe, Merck, Nocion, and Trevi. To mitigate potential conflicts of interest, all final planning decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted planning committee member.

    Patrick Harty, PhD, TFF Content Reviewer and Peer Reviewer, has no relevant financial relationships to disclose.

  • Target Audience

    The target audience is US-based health care professionals who care for patients with RCC, including pulmonologists, allergists, otolaryngologists, primary care providers, nurse practitioners, physician assistants, and speech pathologists.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Summarize best practices for the diagnosis of RCC in conjunction with current evidence-based guidelines
    • Describe the underlying pathophysiology of RCC in accordance with current understanding of the mechanisms involved in cough hypersensitivity
    • Assess ongoing developments in clinical research for emerging therapies to examine their potential impact on improving patient outcomes in RCC
  • Accreditation and Credit Designation Statements

    Accreditation Statement – American Thoracic Society
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation (American Thoracic Society)
    The American Thoracic Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other health care professionals completing this course will be issued a statement of participation.

    Accreditation Statement – The France Foundation
     In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

    Nurses (The France Foundation)
    The France Foundation designates this activity for 1.0 contact hour.

    Physician Assistants (The France Foundation)
    The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 11, 2027. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    ATS and TFF present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ATS and TFF and the commercial supporter(s) assume no liability for the information herein.

  • Provider(s)/Educational Partner(s)

    Provided by the American Thoracic Society

    Other CE credit provided by The France Foundation

  • Commercial Support

    This educational activity is supported by an independent medical educational grant from GSK.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Refractory chronic cough (RCC) presents persistent diagnostic and treatment challenges that can significantly impact patients' quality of life. Join experts from the American Thoracic Society (ATS) and explore evidence-based diagnostic strategies, the neurobiology of cough hypersensitivity, and emerging targeted therapies. Discover how evolving clinical research may shape future treatment approaches and help improve outcomes for patients living with RCC.

  • Disclosure of Relevant Financial Relationships

    It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers, and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org).

    Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

    Amanda Noe, TFF Staff, has no relevant financial relationships to disclose.

    Emily Casabar, MSN, NP-C, AE-C, Planning Committee Member, has served as a consultant for Sanofi and Regeneron. To mitigate potential conflicts of interest, all final planning decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted planning committee member. Content was also reviewed by a non-conflicted planning committee member to ensure it was free from commercial bias, fair-balanced, and based on scientific evidence and/or clinical reasoning.

    Erika Fox, TFF Staff, has no relevant financial relationships to disclose.

    Lauren Eggert, MD, Planning Committee Member and Faculty, has served as a consultant for AstraZeneca, GlaxoSmithKline, Nestwell Health, and Regeneron, and as a speaker for GlaxoSmithKline and Sanofi.

    Melissa Glasner, MSc, Planning Committee Member and TFF Content Reviewer, has no relevant financial relationships to disclose.

    Nicholas Klock, PA-C, Planning Committee Member, has no relevant financial relationships to disclose.

    Peter Dicpinigaitis, MD, Planning Committee Member and Faculty, has served as a consultant for GlaxoSmithKline, Hyfe, Merck, Nocion, and Trevi. To mitigate potential conflicts of interest, all final planning decisions concerning content, learning objectives, and evaluation questions were made by a non-conflicted planning committee member.

    Patrick Harty, PhD, TFF Content Reviewer and Peer Reviewer, has no relevant financial relationships to disclose.

  • Target Audience

    The target audience is US-based health care professionals who care for patients with RCC, including pulmonologists, allergists, otolaryngologists, primary care providers, nurse practitioners, physician assistants, and speech pathologists.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Summarize best practices for the diagnosis of RCC in conjunction with current evidence-based guidelines
    • Describe the underlying pathophysiology of RCC in accordance with current understanding of the mechanisms involved in cough hypersensitivity
    • Assess ongoing developments in clinical research for emerging therapies to examine their potential impact on improving patient outcomes in RCC
  • Accreditation and Credit Designation Statements

    Accreditation Statement – American Thoracic Society
    The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Physician Credit Designation (American Thoracic Society)
    The American Thoracic Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other health care professionals completing this course will be issued a statement of participation.

    Accreditation Statement – The France Foundation
     In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

    Nurses (The France Foundation)
    The France Foundation designates this activity for 1.0 contact hour.

    Physician Assistants (The France Foundation)
    The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 11, 2027. PAs should only claim credit commensurate with the extent of their participation.

  • Disclaimer

    ATS and TFF present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ATS and TFF and the commercial supporter(s) assume no liability for the information herein.

  • Provider(s)/Educational Partner(s)

    Provided by the American Thoracic Society

    Other CE credit provided by The France Foundation

  • Commercial Support

    This educational activity is supported by an independent medical educational grant from GSK.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free